Investment summary

A combination of recently-announced licence agreements and others in the pipeline point to rapid revenue growth over the next two to three years. However, as indicated in last month's trading update, the difficult global consumer climate has delayed the introduction of certain customer products, holding back the immediate performance. Following last year's fund-raising the group had £1.6m at March 2012, sufficient for immediate cash demands and, hopefully, to take the group through to cash-positive trading.

Last updated on 23/04/2012

Industry outlook

The global market for specialist antimicrobial technology is enormous, as awareness of new infections and diseases continues to increase. While many products tend to promise chemical solutions (sometimes solving one problem to create another), a product that can damage the reproductive capacity of various types of bacteria offers considerable attractions to the user. The main challenge for such innovators is to convince major industry players of the efficacy of their technology.

Last updated on 23/04/2012